Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Biomarker Research

Fig. 1

From: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

Fig. 1

RECIST response of melanoma patients. Melanoma patients were divided into responding (n = 12) or non-responding (n = 12) groups based on RECIST 1.1 (response evaluation criteria in solid tumor) guidelines following the Week 12 computed tomography scan. Patients in the responding group showed RECIST CR (complete response) or PR (partial response) while those in the non-responding group had RECIST SD (stable disease) or PD (progressive disease). The percentage of change in target lesions from baseline to Week 12 is shown

Back to article page